Secreted extracellular acid sphingomyelinase (sASM) activity has been suggested to promote atherosclerosis by enhancing subendothelial aggregation and retention of low-density lipoprotein (LDL) with resultant foam cell formation. Compounds that inhibit sASM activity, at neutral pH, may prevent lipid retention and thus would be expected to be anti-atherosclerotic. With the goal of identifying novel compounds that inhibit sASM at pH 7.4, a high-throughput screen was performed. Initial screening was run using a modification of a proven system that measures the hydrolysis of radiolabeled sphingomyelin presented in detergent micelles in a 96-well format. Separation of the radiolabeled aqueous phosphorylcholine reaction product from uncleaved sphingomyelin lipid substrate was achieved by chloroform/methanol extraction. During the screening campaign, a novel extraction procedure was developed to eliminate the use of the hazardous organic reagents. This new procedure exploited the ability of uncleaved, radiolabeled lipid substrate to interact with hydrophobic phenyl-sepharose beads. A comparison of the organic-based and the bead-based extraction sASM screening assays revealed Z´factor values ranging from 0.7 to 0.95 for both formats. In addition, both assay formats led to the identification of sub-to low micromolar inhibitors of sASM at pH 7.4 with similar IC 50 values. Subsequent studies demonstrated that both methods were also adaptable to run in a 384-well format. In contrast to the results observed at neutral pH, however, only the organic extraction assay was capable of accurately measuring sASM activity at its pH optimum of 5.0. The advantages and disadvantages of both sASM assay formats are discussed. (Journal of Biomolecular Screening 2005:225-234) 
INTRODUCTION
H UMAN ACID SPHINGOMYELINASE (ASM) IS AN ENZYME that catalyzes the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. This soluble, Zn 2+ -dependent glycoprotein has a pH optimum of~5.0 but has been shown to hydrolyze sphingomyelin at both acidic and neutral pHs. [1] [2] [3] Two forms of ASM have been described, an intracellular form found in lysosomes and an extracellular secreted form. [4] [5] [6] Both forms are derived from the same ASM gene via differential protein trafficking of a common protein precursor. 5, 6 The secreted form of ASM often requires the addition of exogenous Zn 2+ for activation at acidic pH. However, there are cases in which secreted ASM activity is partially active in the absence of added Zn 2+ . [5] [6] [7] [8] Focal retention of lipoproteins in the subendothelium is a key step in both the initiation and progression of atherosclerotic lesions. Over the past several years, studies have shown that atherosclerotic lesions contain secreted extracellular acid sphingomyelinase (sASM) activity that hydrolyzes sphingomyelin on subendothelial low-density lipoprotein (LDL) at physiologic pH. 3, 9 This sASM activity has been suggested to promote atherosclerosis by enhancing subendothelial aggregation and retention of LDL and foam cell formation. Early atherosclerosis in ApoE (-/-) mice, a widely used model of atherogenesis, is markedly decreased on the ASM (-/-) background, despite similar plasma lipid levels (unpublished results). Therefore, compounds that inhibit extracellular sASM activity may block subendothelial lipoprotein aggregation and thus be anti-atherosclerotic.
Several methods of measuring the activity of sphingomyelinases have been developed. [10] [11] [12] [13] A common technique involves the hydrolysis of radiolabeled sphingomyelin substrate pre-sented in a detergent micelle, followed by a separation of the watersoluble phosphorylcholine product from lipid-soluble sphingomyelin via extraction with an organic solvent such as chloroform/ methanol. 13 This method is amenable to high-throughput screening (HTS) in a 96-well format. 14 In this study, we introduce a modified assay method to measure sASM activity that uses hydrophobic phenyl-sepharose beads to separate aqueous product from uncleaved lipid substrate. We compared the performance of this new assay format to the conventional organic extraction format in an HTS campaign designed to identify inhibitors of sASM at neutral pH. Both assay methods were shown to be acceptable for screening in either a 96-well or 384-well format, and both assays successfully identified sASM inhibitors. A discussion of the advantages and disadvantages of each assay format is presented.
MATERIALS AND METHODS

Materials
Bovine sphingomyelin (choline-methyl- 14 C or choline-methyl- 3 H) and phosphorylcholine (methyl-14 C) were obtained from PerkinElmer/NEN (Boston, MA), with specific activities of 52, 85, and 50 mCi/mmol, respectively. Nonradioactive bovine sphingomyelin was obtained from ICN Biomedicals (Pasadena, CA). Triton X-100 was obtained from Roche Molecular Biochemicals (Indianapolis, IN). Phenyl-Sepharose High Performance Media beads were purchased from Amersham Pharmacia Biotech (cat. 17108201, Newark, NJ). Conditioned media, from Chinese hamster ovary (CHO) cells that were stably transfected with the gene encoding human sASM, were used as the source of the enzyme.
Construction and expression of recombinant human secreted acid sphingomyelinase
The cDNA encoding full-length wild-type human acid sphingomyelinase was obtained from INCYTE (clone 2457184, San Francisco, CA). The acid sphingomyelinase cDNA was PCRamplified with appropriate primers, restricted, and ligated into the Berlex Biosciences proprietary vector pBBS212 digested with EcoRI/HindIII. The resulting construct encoded the full-length human acid sphingomyelinase gene fused with a 6-His tag at the carboxy-terminal end. A thymidine-incompetent (DHFR-minus) CHO cell line, generated at Berlex Biosciences (Richmond, CA), was transfected with the 6-His tagged human acid sphingomyelinase construct by suspending washed cells in transfection medium (Dulbecco's Modified Eagle Medium [DMEM] supplemented with 2% fetal bovine serum [FBS]) and performing a transient transfection using Lipofectamine (Invitrogen, Grand Island, NY) according to the manufacturer's protocol. The cell density was 2 × 10 6 cells/well for a 6-well plate. Medium was harvested 4 d after transfection for Western blot analysis and measurement of sASM activity. Following the initial harvest, cells were subjected to selection by growth in thymidine-poor DMEM medium supplemented with 5% dialyzed, heat-inactivated FBS. The resistant cell population was expanded, followed by the isolation of individual CHO cell clones expressing acid sphingomyelinase by limiting dilution. Clones were adapted to grow in hollow fibers in DMEM supplemented with 5% dialyzed, heat-inactivated FBS and glutamine. Every 3rd day, media were replaced with serum-free DMEM and harvested after 24 h to isolate conditioned media containing recombinant human sASM.
The sequence of recombinant His-tagged sASM present in the conditioned media was verified by partial purification using nickel-NTA chromatography followed by N-terminal sequencing. Enzymatic analysis revealed that the sASM activity in the conditioned media was not dependent on the addition of exogenous Zn 2+ when assayed at neutral pH.
Radiochemical sASM enzyme assay using organic extraction
96-well format
Detergent-solubilized sphingomyelin substrate sufficient for one 96-well plate was prepared as follows. A 280-µL aliquot of 25% Triton X-100 in chloroform/methanol (2:1) was combined with 28.7 µL of 10 mM sphingomyelin in chloroform/methanol (2:1) and 50 µL of 14 C-labeled sphingomyelin, and the mixture was dried under a stream of nitrogen. The radiolabeled mixture was reconstituted with 5 mL of 200 mM HEPES, pH 7.4, and vortexed for 1 min. For screening of sASM inhibitors, the assay was run at pH 7.4. The resulting substrate solution contained 1.4% Triton X-100 and 62 µM sphingomyelin. The assay mixture was prepared by combining the following in each well, using a Multimek ™ liquid-handling system containing a 96-well head (Beckman Coulter, Miami, FL): 50 µL of the substrate preparation, 10 µL conditioned media (4 µg/mL sASM), 10 µL test compound (or buffer) in DMSO, and 30 µL water. This resulted in final assay concentrations of 100 mM HEPES (pH 7.4), 0.7% Triton X-100, 31 µM of sphingomyelin, 0.4 µg/mL sASM, and compounds ranging from 0.05 to 50 µM (with DMSO from 1%-10%). The enzyme reaction was covered and allowed to proceed overnight in a 37°C incubator. Under these conditions, assay linearity was achieved with approximately a 20% conversion of substrate (see Data Analysis section).
The chloroform/methanol extraction procedure for monitoring sASM activity was performed essentially as described previously. 13, 14 Following the overnight incubation, the assay was terminated by addition of 50 µL chloroform/methanol (2:1) using a Quadra ™ liquid-handling system containing a 96-well head (Tomtec, Hamden, CT). The assay plates were sealed with aluminum foil covers and placed on a plate shaker for >30 min, followed by centrifugation at 1000 rpm for 5 min. After careful removal of the foil seals, 25 µL of the aqueous upper layer was gently removed using the Multimek ™ liquid handler (Beckman Coulter) and transferred to a scintillation counting plate. Then, 50 µL of scintillant was added using a 96-well dispenser (Brandel, Gaithersburg, MD), and the amount of radiolabeled product in each well was determined using a TopCount ™ plate reader (PerkinElmer).
384-well format
The amount of the sphingomyelin substrate outlined above was doubled to produce sufficient substrate for one 384-well plate. All of the additions, transfers, and extractions were carried out using a Biomek FX ™ (Beckman Coulter) containing a 384-well head. The assay mixture was prepared by combining the following into each well of a 384-well polypropylene plate (Corning Costar, Corning, NY): 25 µL of the substrate preparation, 5 µL conditioned media (sASM concentration of 4 µg/mL), 5 µL of DMSO or test compound in DMSO, and 15 µL water. This resulted in a final Triton X-100 concentration of 0.7%, a sphingomyelin concentration of 31 µM, 0.4 µg/mL sASM, 100 mM HEPES (pH 7.4), and compound concentrations ranging from 0.1 to 22 µM (with DMSO from 1%-10%). The enzyme reaction was allowed to proceed in a covered plate placed in a 37°C incubator for 16 to 20 h.
Following incubation, the reaction was terminated by the addition of 50 µL chloroform/methanol (2:1). The assay plates were mixed thoroughly using the 384-well pipettor, sealed using aluminum foil seals, and placed on a plate shaker for 15 min. The assay plates were then centrifuged at 1000 rpm for 5 min. After careful removal of the foil seals, 20 µL of the aqueous (upper) layer was gently removed and transferred to a 384-well white OptiPlate ™ (PerkinElmer). Then, 50 µL of scintillant was added to each well using a Multimek ™ (Beckman Coulter) containing a 384-well head. The amount of radiolabeled product was determined as described above.
Radiochemical sASM enzyme assay using bead-based extraction
96-well format
Preparation of the sphingomyelin substrate outlined here produced sufficient substrate for two 96-well plates. A mixture consisting of 200 µL of 4.25% Triton X-100 in chloroform/methanol (2:1), 26 µL of 10 mM sphingomyelin in chloroform/methanol (2:1), and 50 µL of 3 H-labeled sphingomyelin was dried under a stream of nitrogen, reconstituted with 5 mL of 167 mM HEPES (pH 7.4), and vortexed for 1 min. This produced a substrate solution containing 0.17% Triton X-100 and 52 µM sphingomyelin. The enzyme reaction was initiated by combining 30 µL of the substrate preparation alone or substrate-containing test compound with 20 µL of a 1:20 dilution of conditioned media containing sASM (4 µg/mL) into a 96-well polypropylene V-bottom plate (Corning Costar) using a 96-well PlateMate ™ (Matrix, Chicago, IL). The final assay concentrations were 100 mM HEPES (pH 7.4), 0.1% Triton X-100, 31 µM sphingomyelin, 0.08 µg/mL sASM, and compounds ranging from 0.01 to 30 µM (with DMSO ranging from 1%-10%). The enzyme reaction was allowed to proceed overnight in a sealed plate at 37°C. Under these conditions, assay linearity was achieved with approximately a 14% conversion of substrate (see Data Analysis section).
Phenyl-sepharose beads were washed with water to remove ethanol, followed by reconstitution in 2 M NaCl to 5 times the original slurry volume. Following the overnight incubation of the enzyme reaction, the assay was terminated by addition of an equal volume of phenyl-sepharose beads (50 µL) to the reaction mixture using a 96-well PlateMate ™ (Matrix). The assay plates were sealed and placed on a plate shaker for 30 min. The beads were allowed to settle for 30 min. Thereafter, 20 µL of the solution above the beads was transferred to a 96-well clear-bottom polystyrene plate (Corning Costar) using the PlateMate ™ (Matrix) and mixed with 100 µL of scintillant. The amount of radiolabeled product in each well was determined using a Microbeta ™ plate reader (PerkinElmer).
384-well format
Preparation of the sphingomyelin substrate was identical to the procedures used for the 96-well format. All of the additions, transfers, and extractions were carried out using a Biomek FX ™ (Beckman Coulter) containing a 384-well head. The 384-well assay mixture was prepared by combining 30 µL of the substrate preparation alone or substrate-containing test compound with 20 µL of a 1:20 dilution of conditioned media containing sASM (4 µg/mL). The final assay concentrations were 100 mM HEPES (pH 7.4), 0.1% Triton X-100, 31 µM sphingomyelin, 0.08 µg/mL sASM, and compound ranging from 0.1 to 22 µM (with DMSO ranging from 1%-10%). The enzyme reaction was allowed to proceed overnight in a sealed plate at 37°C. Following incubation, the assay was terminated by adding 50 µL of phenyl-sepharose beads (suspended in 2 M NaCl). The assay plates were mixed by the 384well pipettor, sealed, and placed on a plate shaker for 30 min. After settling for 30 min, 20 µL of the solution above the beads was transferred to a 384-well white OptiPlate ™ (PerkinElmer/ Packard). Then, 50 µL of scintillant was added to each well, and the amount of radiolabeled product was determined.
Radiochemical sASM enzyme assays at pH 5.0
Both the sASM organic-based and bead-based extraction assays were run at pH 5.0 under the following conditions to achieve optimal sASM activity and assay linearity at this pH: 1) A 280-µL aliquot of 3.6% Triton X-100 in chloroform/methanol (2:1) was combined with 28.7 µL of 10 mM sphingomyelin in chloroform/ methanol (2:1) and 50 µL of 14 C-labeled sphingomyelin, and the mixture was dried under a stream of nitrogen. The radiolabeled mixture was reconstituted with 5 mL of 200 mM sodium acetate buffer (pH 5.0) and vortexed for 1 min. The final substrate solution contained 0.2% Triton X-100 and 62 µM sphingomyelin. 2) The assay mixture was prepared by combining the following in each well of a 96-(or 384-) well plate, using a Multimek ™ liquidhandling system (Beckman Coulter): 50 µL (25 µL) of the substrate preparation, 10 µL (5 µL) of a 1:10 dilution of conditioned media (0.4 µg/mL sASM), 10 µL ( 
Data analysis
To determine the percent conversion of substrate, the amount of product formed subsequent to the incubation of the enzymatic reaction was divided by the total amount of radioactive sphingomyelin substrate originally added. IC 50 values were determined by nonlinear regression of percent inhibition data by using the 4-parameter logistic equation run by KaleidaGraph software v3.51.
Pharmacopeia library construction
Pharmacopeia's 4-million member combinatorial libraries were created using the ECLIPS ™ (Encoded Combinatorial Library on Polymeric Support) technology. The synthetic strategy used was split synthesis on Tentagel (Rapp Polymere, Tubingen, Germany) beads. Library elements were attached to the beads with a photocleavable/chemically labile linker that facilitated the re-moval of the compound from the bead prior to biological screening. [15] [16] [17] At each synthetic step, encoding molecules were added to identify the substituent added at that step. The encoding molecules were removed after biological screening and identified by electron capture gas chromatography to determine the synthetic history and predicted structure of active compounds. 18, 19 
Library screening methods
Two types of compound libraries were screened for this study. The final screening compound concentration ranged from 1 to 5 µM. One type of library contained a mixture of 10 compounds per well, in solution. These compounds were diluted to the appropriate screening concentration and then directly mixed with the enzyme assay reaction as described above. The 2nd library type contained a mixture of compounds attached to beads. The beads for these libraries were arrayed onto 96-well filter plates at 10 to 20 beads/ well. Beads were photolyzed or chemically treated to selectively remove the compounds from the beads. The resulting eluent was filtered into NUNC V-bottom polypropylene 96-well plates (beads remained on the original filter plates). The V-bottom plates, containing eluted compound, were dried to remove the solvent. Compounds were resuspended in 30 µL of assay buffer containing 167 mM HEPES (pH 7.0), 51 µM sphingomyelin, 0.17% Triton X-100, and 1.7% DMSO (v/v). The enzyme reaction was initiated as outlined above.
RESULTS AND DISCUSSION
sASM assay for HTS using organic extraction
The aim of this work was to run a robust HTS capable of identifying inhibitors of sASM activity at neutral pH. The enzymatic reaction for sASM involves the hydrolysis of the substrate, sphingomyelin, into the 2 products, ceramide and phosphorylcholine. This enzyme reaction is often monitored via the hydrolysis of either 14 Cor 3 H-sphingomyelin, resulting in the generation of radiolabeled phosphorylcholine product and unlabeled ceramide. 12, 13 Using an organic extraction step, the radiolabeled phosphorylcholine can be separated from nonhydrolyzed substrate and ceramide. Although somewhat cumbersome, a 96-well high-throughput organic extraction-based sASM assay was successfully optimized and automated to identify inhibitors of human sASM at neutral pH. The final assay conditions produced linear kinetics of product formation between 0 and 22 h, as shown in Figure 1 , with a signal-tobackground ratio, on average, of >50:1. It should be noted that at neutral pH, the hydrolysis of sphingomyelin by the recombinant human sASM produced by CHO cells was not dependent on the addition of exogenous Zn 2+ for activity. The resulting screening data demonstrated that the 96-well organic extraction assay format maintained excellent reproducibility and generated Z' factor values (an indicator of assay quality) highly acceptable for HTS (Z' factor values ranging from 0.77-0.98). 20 
Development of an HTS assay for sASM activity using a bead-based extraction method
During the course of the screening campaign, alternative methods to the chloroform/methanol extraction process were explored to eliminate the dangers associated with the handling of these substances. It was discovered that phenyl-sepharose beads could capture the hydrophobic, lipophilic components of the sASM reaction and were thus tested for their ability to separate unreacted hydrophobic sphingomyelin substrate from the radiolabeled phosphorylcholine product.
Initial studies demonstrated that the 0.7% Triton X-100 concentration used in the organic extraction assay significantly decreased the efficiency of sphingomyelin binding to the phenylsepharose beads (data not shown). The Triton X-100 concentration needed to be reduced by 7-fold (to 0.1%) for the beads to effectively bind sphingomyelin substrate. Using this lower Triton X-100 concentration, a nonradiolabeled sphingomyelin/ 3 Hsphingomyelin mixture (50 µL) was combined, in a 96-well plate, with various dilutions of phenyl-sepharose beads (50 µL). Plates were shaken for 30 min, followed by a 30-min incubation to allow the beads to settle. Thereafter, a 20-µL aliquot of the mixture above the beads was removed and the amount of 3 H-sphingomyelin determined by scintillation counting. Maximal absorption of the 3 Hsphingomyelin was seen using a 2.5-to 5-fold dilution (v/v) of the stock bead solution (Fig. 2) . A 5-fold (5×) dilution of beads was chosen as the optimal bead concentration and used throughout the remaining studies.
To develop an HTS assay for sASM using this alternative extraction step, it was necessary to demonstrate that the phenylsepharose beads could effectively bind sphingomyelin substrate while leaving the phosphorylcholine product in solution. A comparison of the efficiency of the beads to extract radiolabeled sphingomyelin (either 14 C-or 3 H-sphingomyelin) versus 14 Cphosphorylcholine was thus made. Sphingomyelin in reaction buffer was spiked with either radiolabeled sphingomyelin or radiolabeled phosphorylcholine and added to wells of a 96-well plate (50 µL/well). Then, 50 µL of either 2 M NaCl or a 5× dilution of phenyl-sepharose beads suspended in 2 M NaCl was then added to the wells. The plates were shaken for 30 min, followed by an incubation of 30 min to let the beads settle. Thereafter, a 20-µL aliquot above the beads was removed and the amount of radiolabeled material determined by scintillation counting. As outlined in Table 1 , approximately 97% of the radiolabeled sphingomyelin lipid was removed by the phenyl-sepharose beads under these conditions. In contrast, the nonlipophilic 14 Cphosphorylcholine did not interact with these beads and thus remained in solution.
To complete the development of the sASM bead-based extraction assay, the appropriate amount of sASM enzyme needed to achieve assay linearity using the lower Triton X-100 and optimal phenyl-sepharose bead concentrations was determined. Enzyme concentrations ranging from 0.04 to 2 µg/mL were tested over a time course of 0 to 22 h. Product formation was proportional to the time of incubation when sASM concentrations of 0.05 to 0.4 µg/ mL were used. Figure 1 shows representative time course data for the bead-based assay when an enzyme concentration of 0.08 µg/ mL was used. This was the condition chosen for screening, as it allowed for a 5-fold reduction in sASM reagent compared to the organic extraction method while maintaining an acceptable signalto-noise ratio.
Prior to the initiation of the optimized bead-based assay for HTS, the Km for SM was determined and compared to the Km generated using the organic extraction assay. As shown in Figure 3 , the Km for SM is nearly identical when comparing the organic assay to the bead-based assay (55 µM vs. 66 µM), regardless of the difference in enzyme concentration and lipid-to-substrate ratio between the 2 assay formats. Therefore, a final substrate concentration of 31 µM (1/2 Km) was chosen for compound screening using both assay formats. H-sphingomyelin to phenylsepharose beads. Dilutions of phenyl-sepharose beads in 50 µL, ranging from 2.5-fold to 80-fold, were added to a 96-well plate containing 50 µL of sphingomyelin spiked with 3 H-sphingomyelin (pH 7.4). The plate was vortexed for 30 min, and the beads were allowed to settle for an additional 30 min. A 20-µL aliquot was removed above the beads, and the amount of radiolabeled material was determined by scintillation counting. The data points represent the mean of triplicate determinations, with error bars corresponding to the range of the individual data points. 
C-Phosphorylcholine
Under the final assay conditions, the bead-based format produced a signal-to-background ratio of greater than 10:1, with Z′ factor values averaging 0.75. As illustrated in Figure 4 , a side-byside comparison of the organic extraction assay and the beadbased extraction assay run either in the absence or presence of various concentrations of the tool sASM inhibitor, tellurium tetrabromide (TeBr 4 ), produced similar IC 50 values (1.2 µM and 0.62 µM, respectively). These data indicate that the bead-based extraction assay can be effectively used to measure inhibition of sASM enzymatic activity, similar to the traditional organic extraction assay.
HTS results using the organic and bead-based sASM assays
The organic extraction-based sASM assay method was used to screen a portion of the Berlex Biosciences compound collection (>400,000 compounds) for inhibitors of human sASM activity at neutral pH. In a 96-well format containing 10 compounds per well, this method produced a signal-to-background ratio averaging >50:1 throughout the screen, with an excellent Z' factor value averaging 0.88. Compounds were considered hits if they displayed ≥50% inhibition of control sASM activity. The overall hit rate for this assay was less than 0.2%, with a 90% reconfirmation of the hits, indicating a low false-positive rate. The throughput of the screen was 40 plates per day and could be performed 4 d a week. This allowed for approximately 134,000 compounds to be screened per week, given that the compounds were screened in pools of 10 compounds per well, in duplicate.
Of the validated sASM inhibitors identified, a large number fell into a class of compounds containing a bisphosphonate core structure. Interestingly, a recent publication by Koelzer and colleagues 21 describes a naturally occurring inositol phospholipid, L-αphosphatidyl-D-myo-inositol-3,5-bisphosphate, as a potent and selective inhibitor of acid sphingomyelinase. Although evaluation FIG. 3. Km determination for sphingomyelinase (SM) using the organic and bead-based extraction secreted extracellular acid sphingomyelinase (sASM) assays. Substrate SM concentrations ranging from 3 to 525 µM were tested over a 22-h incubation period using the organic and bead-based sASM assays. The organic assay was run under its screening conditions using 0.4 µg/mL sASM in 0.7% Triton X-100 (A), and the bead-based assay was run under its screening conditions using 0.08 µg/mL sASM in 0.1% Triton X-100 (B). The data points represent the mean of triplicate determinations.
FIG. 4.
Comparison of the concentration-response curves for tellurium tetrabromide generated by each secreted extracellular acid sphingomyelinase (sASM) assay format run in a 96-well plate. Concentrationresponse curves were generated using the reference sASM inhibitor, tellurium tetrabromide, in the CHCl 3 of the bisphosphonate-containing compounds identified from the screen suggested that most were also selective for inhibition of acid sphingomyelinase (data not shown), none of the compounds was pursued further for optimization due to their physicochemical properties.
Following the completion of the above-outlined screening campaign, 3 unique sASM inhibitor templates identified in the organic extraction screen (including one of the bisphosphonate-containing compounds) were tested in a 96-well format using the bead-based extraction assay. As shown in Table 2 , all 3 compounds produced concentration-dependent inhibition of sASM activity with IC 50 values similar to those obtained using the organic extraction method. The deviation between independent determinations was low, with less than a 2-fold spread in activity. These results again suggest that the bead-based sASM assay method yields similar qualitative and quantitative results compared to the organic extraction assay and thus should be acceptable to identify inhibitors of sASM activity in an HTS format.
Based on the validation of the sASM bead-based extraction assay, a significantly larger compound library was screened using this new format. More than 4 million compounds from Pharmacopeia's compound collection were screened using the bead-based assay to identify inhibitors of sASM at neutral pH. In general, the screening was performed with approximately 10 to 20 compounds per well. Active libraries found to contain inhibitors of sASM were rescreened at 1 compound per well. The structures associated with the active wells were then determined as described in Materials and Methods. Similar to the organic extraction method, compounds were considered hits when they inhibited sASM activity ≥50% of control. The overall hit rate for this assay was less than 0.2%. The throughput of this screen was also 40 plates per day, identical to the organic extraction assay. However, the bead-based assay was much simpler to carry out due to the lack of using organic solvents and the ease of plate handling due to the absence of the organic-aqueous liquid interface. This assay was also easily performed 4 d a week, as it was amenable to a full automation, including sealing and shaking. This allowed for a range of approximately 134,000 to 268,000 compounds to be screened a week, given that compounds were screened in pools of 10 to 20 compounds per well.
One of the 70 combinatorial libraries screened against sASM was chosen to illustrate the use of the bead-based extraction meth-odology for HTS of sASM inhibitors. This 3300-member combinatorial library was designed with a core structure containing 3 points of variation. The library consisted of 7 sublibraries and was screened against sASM at 5 compounds per well using a screening concentration of approximately 5 µM. The screening results for an inactive sublibrary from this library are shown in Figure 5A . The results from this plate illustrate the quality of the data that is achieved under HTS conditions using a 96-well assay format. The overall signal-to-background ratio obtained for this plate was 14:1, with Z′ and Z factor values of 0.72 and 0.77, respectively. One of the 7 sublibraries showed activity against sASM when also screened at 5 compounds per well. To identify the structure resulting in the inhibition of sASM activity, the active sublibrary was rescreened at 1 compound per well. Figure 5B shows an example of 1 plate from the 1 compound per well screen. Those wells showing >40% inhibition of control activity were selected for decoding and structure determination. A total of 15 compounds were identified from the screen of more than 4 million compounds, all of which contained a hydroxy-phosphonate core structure. As was the case with the compounds identified from the organic extraction- based sASM screen, none of the compounds proved to be reasonable drug candidates because they were not amenable to chemical optimization.
Adaptation of the sASM organic and bead-based extraction assays to a 384-well format
Following the screening campaigns, the feasibility of moving both the organic extraction and bead-based extraction sASM assays to a 384-well format was explored. Moving to the higher density format would allow for the screening of large compound libraries in a significantly shorter time period with a potential decrease in the cost of consumables and reagents. It was found that the assay volume for the 384-well organic extraction assay could be reduced by half (to 50 µL), whereas the volume for the 384-well bead-based assay could not be reduced below that of the 96-well format (50 µL) due to issues with adequate separation of liquid from the beads.
The resulting signal-to-background ratio for the 384-well organic extraction method averaged 5.5:1, with a Z′ factor value calculated to be 0.54. Although the signal to background decreased an average of 10-fold in comparison to the 96-well format, the calculated Z′ factor value is considered acceptable for screening. In comparison, the signal-to-background ratio for the bead-based extraction assay averaged 7:1 in the 384-well format, resulting in a Z′ factor value averaging 0.51. The well-to-well variability increased significantly in the 384-well format for both assay methods, possibly due to the difficulty in effectively mixing the organic reagents and beads in the 384-well plate. Nevertheless, the results demonstrate that both the organic and bead-based extraction methods could be adapted to the higher density 384-well format, producing acceptable signal-to-background ratio and Z′ factor values suitable for HTS. In comparison to the 96-well format, moving to the 384well format also allows for significant savings in time (4× higher throughput) and cost of consumables for both assays. In the case of the organic assay, a further saving in reagent costs is also realized due to the reduction of its assay volume.
To evaluate the ability of the 384-well organic and bead-based sASM assays to determine inhibitor potencies, concentrationresponse studies using the tool inhibitor, TeBr 4 , were run. As shown in Figure 6 , both 384-well sASM assay methodologies produced nearly identical IC 50 values for TeBr 4 (1.3 µM using the organic, R = 0.991, vs. 2.2 µM using the beads, R = 0.967) that were similar to the respective IC 50 values generated in the 96-well format. However, visual examination of the error bars in Figures 4 and  6 demonstrate that the 348-well organic extraction and bead-based assays produce greater variability in replicate determinations in comparison to the respective 96-well formats. On the basis of these results, we recommend using the 384-well format for HTS and to determine rank-order potencies of compounds run on the same plate with replicate determinations. For the most accuracy in determining compound IC 50 values, the 96-well format is recommended.
Measurement of sASM activity at pH 5.0 using both assay formats
As outlined in the introduction, sASM has been shown to be present in atherosclerotic lesions, where it can hydrolyze sphingomyelin-containing substrates at physiologic pH. 3 Thus, we developed an HTS assay to identify inhibitors of secreted ASM at pH 7.4 for use in the treatment of atherosclerosis. However, both the secreted and lysosomal forms of ASM have a pH optimum of 5.0, and traditionally, the activity of ASM has been measured at this pH. Therefore, it was also of interest to determine whether each assay format was suitable to measure sASM activity at pH 5.0, given that these simplified assay formats may be of use to other researchers in characterizing sphingomyelin metabolism at acidic pH.
Both assays were initially tested at pH 5.0 in a 96-well format. Due to the fact that the sASM used in this study is~17-fold more active at pH 5.0 compared to pH 7.4, the enzyme concentration and reaction times were reduced to achieve assay linearity at acidic pH. Under these modified conditions, micromolar amounts of exogenous Zn 2+ were also added for optimal sASM activity. As shown in Figure 7 , the organic extraction method was successful in measuring sphingomyelin hydrolysis at pH 5.0 in a 96-well format, with a resulting signal-to-background ratio averaging 22:1 and a Z′ factor value averaging 0.81. Further experimentation demonstrated that sASM activity could also be effectively measured in a 384-well format using half the assay volume, resulting in a signal-tobackground ratio of 19:1 and a Z′ factor value averaging 0.62. Surprisingly, however, the bead-based extraction method was not able to effectively measure sASM activity at pH 5.0 in the 96-well format under the modified conditions tested. The data showed extreme variation in replicate wells, with signal-to-background values of less than 2:1. The resulting Z′ factor value averaged 0.06, which is reflective of the low signal dynamic range and the large data variation. This Z′ factor value is considered unacceptable for screening due to poor assay data quality. The high variability seen in the bead-based assay may be due to incomplete separation, at acidic pH, of the unreacted substrate from labeled product by the hydrophobic phenyl-sepharose beads. According to the manufacturer, a decrease in pH results in an apparent increase in hydrophobic interactions. Thus, it may be possible that the nonionic Triton X-100 detergent present in excess in the ASM reaction may compete more effectively with SM for interaction with the beads at pH 5.0 compared to pH 7.4. Further experimentation is required to clarify this issue.
CONCLUSION
This is the 1st report that describes the screening for inhibitors of human ASM. The screen was run at neutral pH due to the fact that this is the likely pH seen by the extracellular secreted form of ASM under most physiologic conditions. 3 It was demonstrated that sASM activity could be measured at neutral pH in a 96-or 384-well HTS format using either an organic or phenyl-sepharose bead extraction method to remove unreacted radiolabeled substrate from product. These 2 different screening protocols were effectively employed to mass screen more than 4 million compounds, resulting in the identification of confirmed, specific inhibitors of sASM with potencies ranging as low as 200 nM. The results suggest that both assay formats could also be easily adapted to assay and screen several other sphingomyelinase enzymes, including the neutral, magnesium-dependent (see Goni and Alonoso 4 and the references therein) and magnesium-independent sphingomyelinases. 22, 23 The advantages of the organic extraction method are its high reproducibility and low data variability, which translates to highquality screening results and ease of miniaturization to a 384-well format. This method has also been shown to effectively measure sASM enzyme activity at pH 5.0 using either a 96-or 384-well format. A clear disadvantage of the organic extraction method lies in the handling and dangers associated with chloroform and methanol, both to the operators and to the equipment. In comparison, the advantages of the bead-based extraction method are its lower cost due to savings in reagents required, as well as its ability to screen for inhibitors of sASM without exposure to organic solvents. The Overall Signal to Background for sASM Organic Extraction Assay Run at pH 5.0 disadvantage of this method lies in its inability to measure sASM activity at acidic pH under the conditions tested in this study. However, neutralization of the sASM assay run at pH 5.0, prior to the addition of the phenyl-sepharose beads, may overcome this limitation. The bead-based separation methodology presented here should be applicable to other lipid-based enzymatic assays, such as phospholipase D. Studies are currently in progress to determine the feasibility of using the bead-based separation format for other lipase-type enzymatic assays and HTS.
